-
-
-
-
-
-
-
Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization
-
-
-
-
-
-
-
Daré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment
-
-
-
-
-
-
-
Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream
-
-
-
-
-
-
-
Dare Bioscience (DARE) and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré’s DARE to PLAY Sildenafil Cream
-
-
-
-
-
-
-
Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update
-
-
-
-
-
-
-
Dare Bioscience (DARE) Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder
-
-
-
-
-
-
-
Dare Bioscience (DARE) Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene Pivotal Study Clinical Trial Sites
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

